Baxter files amended BLA to FDA for HyQvia for primary immunodeficiency

2 December 2013
fda-big

USA-based Baxter International (NYSE: BAX) has completed submission of an amended biologics license application (BLA) to the US Food and Drug Administration to re-initiate the review process for approval of HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) facilitated subcutaneous infusion for the treatment of adult patients with primary immunodeficiency (PI).

Baxter and fellow USA-based partner Halozyme Therapeutics (Nasdaq: HALO) submitted additional preclinical data that was requested from the FDA in 2012, and expect a six-month review period. Halozyme’s shares rose as much as 3.9% to $15.33 in mid-morning trading, while Baxter gained 1% to $69.16.

Could provide valuable option for patients

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical